Free cash flow
Veradermics Free cash flow decreased by 58.7% to -$21.17M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 58.7%, from -$13.34M to -$21.17M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Detailed definition
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Peer comparison
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flowHistorical Data
| Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|
| Value | -$5.92M | -$5.92M | -$5.92M | -$5.92M | -$13.34M | -$21.17M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -125.2% | -58.7% |
| YoY Change | — | — | — | — | -125.2% | -58.7% |
Free cash flow at Other Companies
Frequently Asked Questions
- What is Veradermics 's free cash flow?
- Veradermics (MANE) reported free cash flow of -$21.17M in Q1 2026.
- How has Veradermics 's free cash flow changed year-over-year?
- Veradermics 's free cash flow decreased by 58.7% year-over-year, from -$13.34M to -$21.17M.
- What does free cash flow mean?
- The cash remaining after a company pays for its operating expenses and capital investments.